VIR
Vir Biotechnology, Inc. NASDAQ$10.18
Mkt Cap $1.6B
52w Low $4.16
80.3% of range
52w High $11.66
50d MA $9.53
200d MA $6.77
P/E (TTM)
-3.2x
EV/EBITDA
-1.8x
P/B
1.8x
Debt/Equity
0.2x
ROE
-55.0%
P/FCF
-2.1x
RSI (14)
—
ATR (14)
—
Beta
1.66
50d MA
$9.53
200d MA
$6.77
Avg Volume
3.5M
About
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 f…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23, 2026 | AMC | -0.42 | -0.31 | +26.2% | 7.43 | +32.4% | +27.7% | +34.6% | +25.4% | +22.3% | +25.7% | — |
| Nov 5, 2025 | AMC | -0.70 | -1.17 | -67.1% | 5.40 | -5.0% | -5.2% | -5.0% | -0.6% | +5.7% | +5.7% | — |
| Aug 6, 2025 | AMC | -0.72 | -0.80 | -11.1% | 5.08 | -5.1% | -14.4% | -15.4% | -15.7% | -14.2% | -10.0% | — |
| May 7, 2025 | AMC | -0.83 | -0.88 | -6.0% | 5.61 | -3.2% | -3.6% | -9.3% | -5.5% | -16.2% | -19.8% | — |
| Feb 26, 2025 | AMC | -0.85 | -0.76 | +10.6% | 9.20 | +3.8% | -11.8% | -8.8% | -13.9% | -10.9% | -10.7% | — |
| Oct 31, 2024 | AMC | -0.96 | -1.56 | -62.5% | 7.49 | -4.7% | +23.6% | +25.1% | +28.7% | +35.8% | +30.4% | — |
| Aug 1, 2024 | AMC | -0.93 | -1.02 | -9.7% | 9.73 | -3.6% | -5.3% | -11.1% | -11.6% | -14.6% | -11.4% | — |
| May 2, 2024 | AMC | -0.99 | -0.48 | +51.5% | 9.18 | +10.3% | +13.2% | +11.3% | +8.2% | +3.9% | +4.1% | — |
| Feb 22, 2024 | AMC | -1.14 | -0.86 | +24.6% | 10.30 | +1.9% | +11.9% | +15.5% | +11.0% | +12.6% | +9.1% | — |
| Nov 2, 2023 | AMC | -1.21 | -1.22 | -0.8% | 8.19 | +1.7% | +7.0% | +5.4% | +3.1% | +4.9% | -0.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.91 | $9.20 | +3.3% | +7.3% | +2.1% | +7.2% | +10.0% | +10.9% |
| Feb 25 | Barclays | Maintains | Overweight → Overweight | — | $9.49 | $9.82 | +3.5% | +5.4% | -1.8% | -4.2% | -1.6% | -6.1% |
| Feb 24 | Needham | Maintains | Buy → Buy | — | $7.43 | $9.84 | +32.4% | +27.7% | +34.6% | +25.4% | +22.3% | +25.7% |
| Feb 24 | Morgan Stanley | Maintains | Overweight → Overweight | — | $7.43 | $9.84 | +32.4% | +27.7% | +34.6% | +25.4% | +22.3% | +25.7% |
| Feb 24 | Evercore ISI | Maintains | Outperform → Outperform | — | $7.43 | $9.84 | +32.4% | +27.7% | +34.6% | +25.4% | +22.3% | +25.7% |
| Feb 9 | Needham | Maintains | Buy → Buy | — | $7.19 | $7.19 | +0.0% | +1.3% | +4.5% | +3.2% | +7.2% | +3.9% |
| Dec 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.98 | $5.94 | -0.7% | -2.3% | +0.8% | -0.7% | -3.2% | -0.3% |
| Sep 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.00 | $5.02 | +0.4% | -4.2% | -2.8% | -4.0% | +3.6% | +3.6% |
| Aug 27 | BofA Securities | Upgrade | Neutral → Buy | — | $4.44 | $4.98 | +12.2% | +17.8% | +13.5% | +11.3% | +12.6% | +24.1% |
| May 22 | Needham | Maintains | Buy → Buy | — | $4.51 | $4.45 | -1.3% | +2.2% | -0.2% | +3.3% | +5.5% | +15.1% |
Recent Filings
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis because the filing summary contains only technical XBRL metadata without substantive business information about Vir Biotechnology's financial results, transactions, or strategic developments.
Apr 10
8-K
Vir Biotechnology, Inc. -- 8-K Filing
I cannot provide a meaningful investor summary from this filing, as the document contains only technical SEC metadata and structural references without disclosing substantive business developments, financial results, or corporate actions affecting Vir Biotechnology.
Mar 4
8-K
Vir Biotechnology, Inc. -- 8-K Filing
Vir Biotechnology filed an 8-K disclosure confirming its status as an emerging growth company under SEC regulations, which may affect its reporting obligations and compliance requirements.
Mar 2
8-K
Vir Biotechnology, Inc. -- 8-K Filing
Vir Biotechnology established standard underwriting protections through representations, warranties, and indemnification provisions in a securities offering agreement with underwriters.
Feb 26
8-K · 8.01
!! High
Vir Biotechnology, Inc. -- 8-K 8.01: Material Event / Announcement
Vir Biotechnology will present updated Phase 1 data for cancer candidate VIR-5500 at an upcoming oncology conference, potentially influencing investor sentiment on the drug's development progress.
Feb 23
8-K · 7.01
! Medium
Zura Bio Limited Class A -- 8-K 7.01: Regulation FD Disclosure
Zura Bio disclosed material information via press release on February 23, 2026, subject to Regulation FD requirements without admitting materiality determinations for investor consideration.
Feb 23
Data updated apr 27, 2026 7:44am
· Source: massive.com